Sodium taurodeoxycholate hydrate

Research use only, not for human use.

Sodium taurodeoxycholate hydrate has been used in a study to assess the effect of submicellar concentrations of bile salts on the lipid bilayer membrane.

Sodium taurodeoxycholate hydrate has been used in a study to assess the effect of submicellar concentrations of bile salts on the lipid bilayer membrane.

The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals.Taurodeoxycholate inhibits the binding of N-3H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC50 of 170 μM.Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation.Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells. Cell Proliferation Assay Cell Line:IEC-6 and caco-2 cells Concentration:0, 0.05, 0.50, and 1.00 mM Incubation Time:1, 2, 4 and 6 days Result:Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner.Cell Cycle Analysis Cell Line:IEC-6 cells Concentration:0, 0.05, 0.50, and 1.00 mM Incubation Time:24 h Result:Significantly increased cells in S phase and decreased cells in G1-phase.Western Blot Analysis Cell Line:IEC-6 cells Concentration:0.5 mM Incubation Time:1 and 6 days Result:Significantly increased c-myc protein expression.

Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis. Animal Model:C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsisDosage:0.5 mg/kg Administration:Intravenous injection, 30 min or 24 h after LPS injection Result:Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.

Taurodeoxycholic acid sodium salt monohydrate

Others

Other Targets

Others

——

——

207737-97-1

539.7

C26H44NO6S.Na.H2O

>98% (HPLC)

In Vitro:?H2O : 100 mg/mL (191.68 mM)

C[C@H](CCC(NCCS(=O)([O-])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C.[H]O[H].[Na+]

——

(-20℃)

With Ice Pack

≥ 2 years